Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Thursday, October 29, 2026

⚡ Executive Takeaway

The detail worth sitting with is not that retatrutide won, it is who Lilly chose to fight. TRANSCEND-T2D-2 was designed against Ozempic's highest diabetes dose, and the next head to head in the program, TRIUMPH-5, is aimed at Lilly's own tirzepatide. That sequencing tells you what the top of the incretin market now runs on: superiority over the reigning standard, measured in the standard's own units, is becoming the only argument payers and prescribers will price. Placebo wins stopped moving share months ago; from here, every new entrant inherits a comparator bar that gets higher each time one of these trials reads out. It also reframes incumbency. Being the comparator is expensive in the short run, Novo wears a weight number from someone else's press release, but it is the position everyone is paying to attack, and the attacker is already scheduling a fight against itself before anyone else gets in the ring. Watch whether Novo answers with head to head designs of its own, because in this market, declining the format is starting to read as an answer.

The full arm table, the guidance progression, and the Biogen quarter brand by brand, all below. 👉 Read Full Analysis

💉 The Head to Head Era Begins

Retatrutide beat Ozempic 2 mg on blood sugar and more than doubled its weight loss in the first Phase 3 between incretin medicines. LLY | NVO

TRANSCEND-T2D-2 randomized 1,298 adults with type 2 diabetes inadequately controlled on metformin 2:2:1 to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg, once weekly for 80 weeks, open label. The 12 mg win on A1C is statistically controlled; the matching 9 mg figure is nominal, a prespecified secondary, and that distinction will matter for the label. Tolerability is the price: 7.9% of 12 mg patients stopped for side effects versus 2.7% on Ozempic. Lilly stated no filing timing; Leerink's David Risinger modeled $15 billion in 2032 sales against a consensus near $10 billion, per BioPharma Dive. The session stayed calm: LLY +0.5%, NVO −1.0%, settled closes, our arithmetic.

🫀 Three Cuts and a Cyber Bill

Boston Scientific guided 2026 down for the third time this year and put a roughly $150 million revenue number on the August cyberattack. BSX

Third quarter sales grew 1.5% to $5.138 billion with adjusted EPS of $0.73, and the new full year guide, about 4.25% reported growth and $3.16 to $3.18, sits a long way from February's 10.5 to 11.5% and $3.43 to $3.49; the fourth quarter is guided to a 1 to 3% sales decline, all per the company's release. The cyber number, roughly $150 million of lost third quarter revenue, comes from the company's remarks reported by MedTech Dive, which also carried the quieter story: Watchman fell 6% and electrophysiology 5%, on referral pattern changes and pulsed field ablation competition, and chief executive Mike Mahoney said growing sales and adjusted EPS next year will be a challenge. The $14.5 billion Penumbra close slips to early 2027. BSX closed at 42.43, down 5.8%, ours.

🧬 Biogen Grew 11% and the Market Shrugged

Biogen's growth portfolio rose 49% in its first full Apellis quarter, the EPS floor moved up, and the stock still fell 3.4%. BIIB

Revenue reached $2,804.1 million, up 11%, with Spinraza up 23%, Skyclarys up 34%, Syfovre up 27% and Zurzuvae up 53%, per the release; Alzheimer's collaboration revenue rose 60% to $68.4 million as Eisai recorded $202 million of global in market Leqembi sales. The GAAP line shows a $0.14 loss on transaction charges, and guidance moved the right way at both layers: the reported floor rose to $12.20 and the underlying range tightened to $15.95 to $16.75. What the market priced instead is the readout stack ahead: litifilimab's Phase 3 lupus toplines land in the first half of December, with the cutaneous lupus study and felzartamab in antibody mediated rejection in the first half of 2027. Chief executive Christopher Viehbacher called it a return to growth; BIIB closed at 244.05, down 3.4%, ours.

🧫 Iovance Says Positive, Shows Nothing Yet

Iovance called its registrational lifileucel lung cancer data positive and scheduled the numbers for a Thursday 8:30 am ET webcast. IOVA

The 7:00 pm release covers the registrational Phase 2 cohorts of IOV-LUN-202, lifileucel TIL therapy in previously treated nonsquamous metastatic non small cell lung cancer, and discloses no efficacy figures at all, so we print this as a scheduled disclosure event with outcomes unknown and grade it tomorrow night. One vintage guard for readers checking their own feeds: the interim numbers circulating from November 2025, a 25.6% response rate in 39 patients, are the old dataset, not what Thursday brings. IOVA closed at 14.81, up 1.6%, before the notice landed; Thursday is the first reaction session.

🏛️ Washington Cracks the Peptide Door

Endpoints News reported Wednesday that HHS will allow compounding of certain wellness peptides, the policy AP traced to White House review two weeks ago. Multiple

The background, from the Associated Press on October 15: HHS submitted an interim access policy to the Office of Management and Budget that would let pharmacies temporarily compound some of the most popular peptides, BPC-157 among them, through what AP described as enforcement discretion, after a July advisory panel recommended six of seven peptides over the objections of FDA staff scientists. The FDA's own newsroom showed nothing on this through tonight's check, and no agency document has posted, so every detail here is attributed and the scope remains unverified. If it lands as described, the compounding fight that defined the GLP-1 shortage era gets a wellness sequel, this time with the agency holding the door open.

🧪 HUTCHMED Banks a US Option on Sovleplenib

The FDA granted orphan drug designation to HUTCHMED's oral Syk inhibitor in primary immune thrombocytopenia, with worldwide rights still unpartnered. HCM

The 8:00 pm release puts sovleplenib, a once daily oral spleen tyrosine kinase inhibitor, in line for seven years of US market exclusivity on approval, plus fee waivers and trial tax credits. China filings in primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia are already under NMPA review on the ESLIM-01 and ESLIM-02 trials, and the release names no US trial or filing timeline. The strategic read is the rights line: HUTCHMED retains sovleplenib worldwide, and a US designation on an asset already filed in China is exactly the package this year's licensing market has paid up for, two days after savolitinib's SAFFRON win put the company's chemistry in the NEJM. HCM closed at 13.32, down 3.5%, before the notice; Thursday is the first reaction session.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →